Wegovy Pill (Oral Semaglutide), Where to Get It Online in 2026
On December 22, 2025, the FDA approved Novo Nordisk's oral Wegovy (semaglutide 25 mg tablets) for chronic weight management, the first oral GLP-1 ever approved for an obesity indication in the US. This is a different product from Rybelsus, which has been on the market since 2019 but tops out at 14 mg and is approved only for type 2 diabetes. The pivotal OASIS 4 trial reported −16.6% mean body-weight loss at 64 weeks in adherent participants on the 25 mg dose. figures that put it on roughly the same efficacy plane as injectable Wegovy 2.4 mg without a head-to-head trial to confirm parity. As of writing, FuturHealth is the only consumer telehealth platform we have verified is actively dispensing the Wegovy pill at scale.
Reader-supported, we may earn a commission through links on this site. Rankings are editorially independent. Disclosure · Methodology
Semaglutide 25 mg in oral tablet form, formulated with the SNAC absorption enhancer (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate), the same delivery technology used in Rybelsus. The 25 mg obesity-indicated dose is roughly 1.8× the highest Rybelsus diabetes dose. Mechanistically identical to injectable Wegovy: a long-acting GLP-1 receptor agonist that slows gastric emptying, increases satiety, and reduces caloric intake. The differentiator is route, not molecule.
Adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidaemia, OSA), who prefer a daily oral tablet to a weekly injection. The tablet form is most useful for needle-averse patients, frequent travellers who don't want to manage refrigerated pens, and patients who already take other once-daily morning medications and can absorb the fasted-window protocol into an existing routine.
Titration follows a four-step, ~16-week schedule: 1.5 mg (days 1–30) → 4 mg (days 31–60) → 9 mg (days 61–90) → 25 mg maintenance (day 91+), escalating roughly every 30 days if tolerated. The fasted-window protocol is strict: the tablet must be taken on an empty stomach with no more than 4 oz of plain water, at least 30 minutes before eating, drinking anything other than water, or taking any other oral medication. Coffee, supplements, and most other oral meds break the absorption window.
Verified Oral GLP-1 Pill Offers
FuturHealth
GLP-1 weight-loss platform combined with personalised nutrition and fitness coaching.
What the Studies Actually Show
The evidence below comes from the OASIS 4 trial (the pivotal study for the December 2025 FDA approval of oral semaglutide 25 mg for weight management) and the FDA prescribing information. OASIS 4 data are from the adherent-participant analysis presented at EASD 2025.
| Endpoint | Finding |
|---|---|
| Mean weight loss (OASIS 4, 64 weeks, 25 mg once-daily)1 | −16.6% body weight with full adherence vs −2.7% placebo in adults with obesity |
| Participants achieving ≥20% weight loss (OASIS 4, adherent subset)1 | One-third of adherent participants achieved ≥20% weight loss vs <3% on placebo |
| Serious adverse events (OASIS 4)1 | 3.9% with oral semaglutide vs 8.8% with placebo — fewer serious events in the treatment arm |
| Prediabetes reversal (OASIS 4 post-hoc)1 | 71.1% of participants with prediabetes at baseline achieved normal blood glucose by week 64 |
| Cardiovascular risk factors (OASIS 4 post-hoc)1 | Improvements in blood pressure, glycemic control, and composite cardiovascular risk markers observed alongside weight loss |
| FDA approval date2 | December 22, 2025 — first oral GLP-1 receptor agonist approved specifically for chronic weight management in adults (not just type 2 diabetes) |
| Dosing2 | Once-daily oral tablet; titration from 1.5 mg → 4 mg → 12 mg → 25 mg over approximately 20 weeks. Must be taken on an empty stomach with ≤4 oz water, 30 min before food/drink/other medications |
| How it differs from injectable Wegovy1 | Same active ingredient (semaglutide) but oral route. Injectable Wegovy 2.4 mg weekly achieved −14.9% in STEP 1; oral 25 mg daily achieved −16.6% in OASIS 4 — broadly comparable efficacy, different administration route Direct head-to-head trial between oral and injectable Wegovy has not been published. OASIS 4 and STEP 1 used different populations and protocols; cross-trial comparisons are approximate. |
| How it differs from Rybelsus (oral semaglutide for diabetes)2 | Rybelsus is approved for type 2 diabetes at doses up to 14 mg. Wegovy tablets are approved for chronic weight management at 25 mg — a higher dose with a distinct obesity indication |
Frequently Asked Questions
- OASIS 4 — Novo Nordisk press release / GlobeNewswire 2025 · Novo Nordisk. Oral semaglutide 25 mg delivered 16.6% weight loss in people with obesity in the OASIS 4 trial. GlobeNewswire, September 17, 2025.
- FDA approval — Novo Nordisk press release, December 22 2025 · Novo Nordisk. FDA approves Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults. PR Newswire, December 22, 2025.
- FDA prescribing information — Wegovy tablets (semaglutide 25 mg) · U.S. Food and Drug Administration. Wegovy (semaglutide) tablets prescribing information. NDA 218316. December 2025.
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.